A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function

A total of 16 subjects will be recruited and divided between the following two Groups: Group 1: 8 subjects with severe hepatic impairment Group 2: 8 subjects with normal hepatic function (control group) On Day 1, subjects will receive a single oral dose of 200 mg Elacestrant (2 x 100 mg tablets). Safety assessment and blood sampling for Elacestrant analysis on plasma will be performed at predefined time points up to 240 hours post. The total duration of study participation for each subject (from screening to the follow up call) is anticipated to be approximately 6 weeks.